are you kidding...I loaded... this will be 33.50 in 6 months. Nice shakeout that gave me this opportunity.
Kitty says it still cheap. How is VPHM's forward PE 40 and snts is only 15...mid 30's easy.
Orally active in the Rat with no sleepiness or dizziness. A reasonable dose of 375 BID in human models ...Say Bye bye to lyrica and Neurontin these are junk in comparison. I don't think we are grasping how good a drug ZLCS is sitting on.
you'll be buying this for 12 soon...the bigs are starting to show up on the shores...this one is a no brainer. Hey Kitty How much do have now? i'm loaded for bear.
I don't know about 1 billion in sales but this is definitely a 200 million dollar drug. The oral/IV administration certainly is a big enough differentiator that will assure that.
Also, I reviewed the Phase2 data and from I can tell it was quite impressive with a very tight confidence interval. this will be 12-14 easily.
With these purchases cbst will be bought out as they are the leader in the antibiotic space...no question. Pfizer will most likely pick up cbst to prop up its beleaguered pipeline and to become the leader in antibiotics. Cbst will probably climb into the 70's for sure now.
I'm just come from Tsrx after doubling my money...Gosh tsrx was a no brainer, a next generation Zyvox, tedizolid will be huge.
Anyway, This Co. finds itself in a similar situation... essentially we got ourselves a tygacil follow-on...only with eravacycline its oral/IV and given less frequently where Tygacil is just IV. This one will take some time but a double here is a given.
wait a second...incrementally better? did i hear that correctly? 6 days vs. 10 days on efficacy, almost no neuropathies, and clearly better drug-drug interaction profile. I would not call this incremental...say bye bye to ZYVOX.
easy double as well...but too soon at this point. Just ride tsrx for now then double back for ttph later...JMO.
Tedizolid stay in hospital is 24 hrs plus 5 day oral at home no return trip to the hospital...sorry durata dalbavancin comes in second.
One quick look at the data form the phase 3s and one can see that is not as effective as linezolid or Vanco...This must be the real reason why Pfizer dumped it...Cmon how many phase 3s does the drug need its been in development for what 12 years now.
there is no offer for optr; this is just a diversion. The real attack will come on the Tsrx beaches. The bigs need everyones attention on optr while they prepare to launch their real attack on TSRX to get as many shares as possible for their triple A clients...so obvious.